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This editorial refers to ‘What is the real atrial fibrillation
burden after catheter ablation of atrial fibrillation? A
prospective rhythm analysis in pacemaker patients with
continuous atrial monitoring’† by D. Steven et al., on
page 1037
Atrial fibrillation (AF) is associated with embolic accidents and
heart failure as well as increased mortality.1 Associated heart
disease is known to be an important factor determining mortality.1
On the other hand, the significance of the arrhythmia in patients
with lone AF has been more difficult to prove perhaps because
of the difficulty of measuring the time spent in AF, the burden of
AF, and thus establishing a dose–effect relationship. Somewhat
paradoxically, a recent consensus statement2 does not distinguish
between the prognostic implications of paroxysmal vs long-
standing chronic AF while at the same time recommending antic-
oagulation before cardioversion of long-lasting AF but not for AF
of recent onset.
From a mechanistic point of view, the longer the atria remain in
fibrillation, the greater the stasis and the likelihood of stasis-
generated thrombi. In experimental models, short durations of
AF result in less electrical and structural atrial remodelling.3 The
duration of atrial stunning following cardioversion may also be pro-
portional to the duration of preceding AF,4 favouring continuing
stasis despite the restoration of sinus rhythm. A systemic
embolic accident also requires the ejection of left atrial thrombi
into the systemic circulation, and reversion to sinus rhythm can
provide a sufficiently powerful atrial appendage contraction.
One possible reason why the AF burden is not recognized as a
prognostic marker may be the difficulty of reliably estimating it. AF
is often intermittent and capricious. The patients’ perception of
fibrillation is frequently far from perfect and often this arrhythmia
generates no symptoms. The administration of AV nodal blocking
drugs can modify or suppress symptoms. Some patients may
unconsciously adapt their lifestyle to avoid symptoms resulting
from heart rate acceleration, while still others may possibly have
altered sensibility (neuropathies, surgical denervation, etc.).
Estimating AF burden
A resurgence of interest in estimating AF burden is undoubtedly
the result of the popularity of catheter ablation (CA). In the
absence of justification for an AF burden threshold for compli-
cations (chiefly embolic), complete elimination has been the
accepted goal of CA of AF. Instead of estimating the residual AF
burden, most groups try to maximize the chances of detecting
residual AF, relying on the absence of documented AF and symp-
toms as the standard of a successful intervention.
To this end, 24 h and 7 day Holter recordings,5 event monitors,
and transtelephonic monitoring6 have all been utilized. Clearly the
probability of detecting transient arrhythmias increases directly in
proportion to the monitored time period. Thus 7 day Holter
recordings are more sensitive than 24 h Holter recordings.5
Event monitors are best used to analyse symptomatic events,
while transtelephonic monitoring provides a convenient and fre-
quent snapshot and can be used as an event monitor. Sensitivity
is however limited by the surveillance period, while the specificity
of arrhythmia diagnosis using a typical 3-lead surface ECG over any
length of time is not optimal. The skin electrodes are difficult to
maintain over longer periods because of soreness or allergic reac-
tions, and are incompatible with some routine activities. It is there-
fore impractical to extend surface ECG monitoring beyond 7 days.
Purerfellner et al.7 were probably the first to use the atrial
Holter function of implanted pacemakers for monitoring purposes
in patients who underwent CA for AF. Verma et al.8 used mode
switch episodes as an estimate of the AF burden. This latter
measure is clearly a less precise measure of the AF burden when
compared with a ‘full disclosure’ measurement of a high atrial
rate event burden such as in the study of Purerfellner et al.7
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Steven et al.9 describe AF burden measurement in a group of 37
patients with implanted dual-chamber pacemakers undergoing CA
of paroxysmal or persistent AF. Although a variety of devices were
implanted, the majority possessed beat to beat detection of high
rate episodes, and intracardiac markers and electrograms were
reviewed to verify the arrhythmia diagnosis. The authors observed
a reduction in AF burden immediately after ablation, and confirmed
a further reduction in the first 3 months. They did not, however,
include a control group monitored without the help of implantable
devices. During the follow-up period, none of the patients with
pacemaker documentation of AF recurrence remained completely
asymptomatic. While this insight provides support for simple
symptomatic follow-up, all their patients were highly symptomatic
before ablation and we do not know whether the same results
would be obtained for patients with pre-existing asymptomatic
AF. The absence of a correlation between symptoms and arrhyth-
mia documentation in the patients of Steven et al. prior to ablation
is a limitation. The authors’ conclusions with regard to the
reliability of symptomatic follow-up after CA of AF must therefore
be received with caution.
Implantable pacemakers are clearly not suited for a role as an
arrhythmia surveillance device. They are complex, expensive, and
vulnerable to potentially devastating complications because they
are attached by leads to the endocardium. The presence of intra-
cardiac leads may be a hindrance during catheter manipulation;
moreover, they can be damaged or dislodged during the
procedure.
Simple, inexpensive, easy to implant (and explant!) leadless
devices may be able to fulfil many of the requirements described
above. The recently modified Reveal XT (Medtronic) is surely
the first of a growing trend. Although relying principally on R
wave irregularity and presently limited in its memory capacity,
such devices offer truly constant surveillance. Further miniaturiza-
tion, multiple small leadless electrodes, and a larger memory could
allow refined surface ECG diagnostics, robust measurement of AF
burden, and even vectorial analysis.
After CA of AF, the longer the follow-up, the greater the cer-
tainty about rhythm outcome. An implantable rhythm monitoring
device may achieve high (or higher) levels of certainty within a
shorter follow-up and provide a ‘hard’ indicator of the efficacy of
CA. Implantable devices are ideal in order to prove (or disprove)
the relationship of atrial burden to the complications of AF, e.g.
embolic accidents. Recent data suggest that high rate atrial epi-
sodes lasting more than a day do correlate with an increased inci-
dence of embolic accidents.10 Although the work of Stevens et al.9
has provided support for the importance of AF burden, prospec-
tive data in larger cohorts and with a longitudinal follow-up are
needed hopefully to validate AF burden as a predictor of
AF-related embolic complications.
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